Related Experiment Videos
Markers of thrombotic activity in arterial disease
Insights
Platelet degranulation products, beta-thromboglobulin (BTG) and fibrinopeptide A (FPA), were elevated in peripheral vascular disease (PVD) patients, indicating increased thrombotic activity. These markers may help assess disease severity and treatment effectiveness.
Area of Science:
- Biochemistry
- Hematology
- Vascular Medicine
Background:
- Peripheral vascular disease (PVD) is often associated with heightened thrombotic activity.
- Biomarkers reflecting platelet degranulation and fibrinolysis are crucial for understanding PVD pathophysiology.
- Assessing thrombotic markers can aid in managing PVD and its complications.
Purpose of the Study:
- To measure levels of beta-thromboglobulin (BTG) and fibrinopeptide A (FPA) in asymptomatic subjects and PVD patients.
- To investigate the correlation between these markers and the presence of PVD and bypass grafts.
- To evaluate the potential utility of BTG and FPA as indicators of disease severity, prognosis, and therapeutic response.
Main Methods:
- Blood samples were collected from three groups: asymptomatic subjects (n=26), PVD patients (n=17), and PVD patients with bypass grafts (n=12).
- Levels of beta-thromboglobulin (BTG) and fibrinopeptide A (FPA) were quantified using appropriate assays.
- Serial measurements were performed in patients with bypass grafts to observe trends over time.
Main Results:
- Mean BTG and FPA levels were significantly elevated in PVD patients (groups 2 and 3) compared to asymptomatic subjects (group 1).
- Elevated levels in PVD patients suggest increased platelet activation and fibrinolytic activity.
- Serial assays in group 3 patients indicated a potential downward trend in marker levels over time.
Conclusions:
- Elevated BTG and FPA levels are indicative of increased thrombotic activity in patients with peripheral vascular disease.
- These hemostatic markers may serve as valuable tools for assessing PVD severity and prognosis.
- BTG and FPA could potentially monitor graft healing, patency, and the efficacy of therapeutic interventions in PVD management.
Abstract:
Levels of the platelet degranulation product beta-thromboglobulin (BTG) and the fibrinogen degradation product fibrinopeptide A (FPA) were measured in 26 asymptomatic subjects (group 1), 17 patients with peripheral vascular disease (PVD) (group 2), and 12 patients with PVD and bypass grafts (group 3). Mean BTG and FPA levels were elevated in both groups 2 and 3, indicating increased thrombotic activity in patients with PVD. Results of serial BTG and FPA assays in group 3 patients suggested a trend downward. These markers may be useful for estimating disease severity and prognosis, extent of graft healing and patency, and efficacy of therapeutic intervention.